-
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Wortelboer, N., Kent, S., Konings, I. R., van Ommen-Nijhof, A., van der Noort, V., van den Pol, E., Guerrero Páez, C., van Bekkum, M. L., van den Berkmortel, F. W. P. J., Droogendijk, H. J., Houtsma, D., Oosterkamp, H. M., van der Padt-Pruijsten, A., Siemerink, E. J. M., Tol, J., van Zweeden, A. A., van Leeuwen-Stok, A. E., Sonke, G. S., Jager, A. & Blommestein, H. M., 9 Dec 2025, In: Eur. J. Cancer. 231, 116051.Research output: Contribution to journal › Article › Academic › peer-review
-
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial
Jongbloed, E. M., Wortelboer, N., de Weerd, V., Beaufort, C. M., Ruigrok-Ritstier, K., van, M. N., Kraan, J., van Zweeden, A. A., van der Padt-Pruijsten, A., Hamming, L. C., Konings, I. R., Sonke, G. S., Oomen-de Hoop, E., Martens, J. W. M., Jager, A. & Wilting, S. M., Nov 2025, In: Nature Medicine. 31, 11, p. 3662-3667 6 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Correction to: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer (Nature, (2024), 636, 8042, (474-480), 10.1038/s41586-024-08035-2)
Sonke, G. S., van Ommen-Nijhof, A., Wortelboer, N., van der Noort, V., Swinkels, A. C. P., Blommestein, H. M., Guerrero Paez, C., Mol, L., Beeker, A., Beelen, K., Hamming, L. C., Heijns, J. B., Honkoop, A. H., de Jong, P. C., van Rossum-Schornagel, Q. C., van Schaik-van de Mheen, C., Tol, J., Tromp-van Driel, C. S., Vrijaldenhoven, S. & van Leeuwen-Stok, A. E. & 1 others, , 14 Aug 2025, In: Nature. 644, 8076, p. E32Research output: Contribution to journal › Comment/Letter to the editor › Academic
- All publications
